Opt-Out Syphilis Screening in ED Improves Screening, Diagnosis
By Lori Solomon HealthDay Reporter
FRIDAY, Sept. 13, 2024 -- Implementation of opt-out emergency department syphilis screening leads to a dramatic increase in screening and diagnosis, especially among pregnant individuals, according to a study published online Sept. 10 in Open Forum Infectious Diseases.
Kimberly A. Stanford, M.D., from University of Chicago, and colleagues examined trends in syphilis screening and diagnosis before and after implementation of an opt-out emergency department syphilis screening intervention in May 2019.
The researchers found that syphilis screening increased from 3.6 to 24.4 percent of encounters. Presumed active syphilis infection (PAI) increased 288 percent during the study period, from 161 patients (3.1 percent of those screened) to 624 patients (1.7 percent of those screened). Similarly, the proportion of women with PAI increased from 25.6 to 42.5 percent, despite no change in the proportion of women screened. Following implementation, 23.6 percent of PAI were tested for a urogenital sexually transmitted infection (STI) in the emergency department and 9.0 percent presented with symptoms of an STI by diagnosis code. Screening increased from 5.9 to 49.9 percent of encounters among pregnant people, and syphilis diagnosis increased 750 percent (from two cases to 15).
“Opt-out screening will be an important strategy in the effort to address the syphilis epidemic,” the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Rx Up for Stimulants and Antidepressants, Down for Opioids, 2019 to 2022
MONDAY, Sept. 16, 2024 -- Overall prescription volumes for stimulant and antidepressant medications increased from 2019 to 2022, while prescription volume for opioids decreased...
Tusamitamab Ravtansine Does Not Extend Survival With Nonsquamous NSCLC
FRIDAY, Sept. 13, 2024 -- Tusamitamab ravtansine (tusa rav), an immunoconjugate, does not improve progression-free survival (PFS) in patients with previously treated advanced...
At Least One in Five People Has Obesity in Each U.S. State
THURSDAY, Sept. 12, 2024 -- Statistics from 2023 on U.S. obesity rates reveal that in every U.S. state, one in every five people now has obesity, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.